Many patients with allergic disorders continue to have uncontrolled symptoms despite new and better pharmacologic options. Novel biologic agents that target specific and critical pathophysiologic pathways have been developed to better manage these patients. The utility of biologic agents for the management of allergic diseases has been facilitated by recent advances in better characterizing patients, including identification of relevant biomarkers that predict clinical responsiveness. This has led to the ability to phenotype and endotype patients, allowing for a more rational approach to picking a specific biologic agent for a specific patient.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2qsbvFP
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
Background Hyperthyroidism is associated with increased thrombotic risk. As contact system activation through formation of neutrophil extrac...
-
CBN News Cancer Took Most of His Tongue, but This Pastor Is Still Singing ... CBN News A youth pastor in San Diego, California is not ...
-
Abstract Ocean acidification increases the amount of dissolved inorganic carbon (DIC) available in seawater which can benefit photosynthes...
-
Inhibition of epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) signaling is highly effective in a subgroup of no...
-
Abstract Diphenylarsinic acid (DPAA) is an organic arsenic compound used for the synthesis of chemical weapons. We previously found that th...
-
Pugazhenthan Thangaraju, Sajitha Venkatesan, MK Showkath Ali Indian Journal of Community Medicine 2018 43(1):58-59 from #AlexandrosSfa...
-
IJMS, Vol. 18, Pages 1601: Updated Insight into the Physiological and Pathological Roles of the Retromer Complex International Journal of M...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου